Clinical and economic implications of false-positive heparin-induced thrombocytopenia immunoassays: utility of the 4T score.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
05 Jun 2024
05 Jun 2024
Historique:
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
aheadofprint
Résumé
Heparin-induced thrombocytopenia (HIT) is a prothrombotic condition induced by platelet-activating IgG antibodies that recognize PF4/heparin complexes. Diagnosis of HIT relies on enzyme immunologic assays (EIAs) and functional assays [serotonin release assay (SRA)]. Our institution uses a latex immunoturbidimetric assay (LIA), which has shown a positive-predictive value (PPV) of 55.6%, and a negative-predictive value (NPV) of 99.7%. The low PPV of EIAs/LIAs, in combination with the clinical delay in obtaining results of a SRA, commonly leads to a false-positive diagnosis of HIT and inappropriate treatment. We performed a single-institution retrospective study at a large tertiary center to assess patient management decisions and economic costs following a false-positive HIT (LIA) test. This study found an 89.5% incidence of false-positive HIT (LIA) tests. 97.4% of patients underwent anticoagulation changes. 69.6% of patients were switched to argatroban. Of patients with a false-positive HIT immunoassay (LIA), 42 (40.7%) patients were on a prophylactic dose of anticoagulation at the time of HIT (LIA) positivity, of which 22 (52.4%) were switched to full anticoagulation with either argatroban or fondaparinux. Of the 22 patients switched to full anticoagulation, 15 (68%) had low-probability 4T scores. Seven (8.8%) of patients had bleeding events after HIT (LIA) positivity. All seven patients were switched to argatroban from a full-dose heparin anticoagulation. Five of the seven patients were considered major bleeds. Utilization of argatroban incurred substantial costs, estimated at approximately $73 000 for false-positive HIT cases. False-positive HIT (LIA) tests contribute to unwarranted anticoagulation changes, increased bleeding risks, and substantial healthcare costs. Incorporating the 4T score into diagnostic algorithms may help mitigate these risks by guiding appropriate clinical decisions. Future research should focus on refining diagnostic approaches and standardizing management strategies to improve patient outcomes and cost-effectiveness in HIT diagnosis and management.
Identifiants
pubmed: 38874904
doi: 10.1097/MBC.0000000000001314
pii: 00001721-990000000-00157
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Alkoutami G, Mansour M, Abdulhamid I. Induced thrombocytopenia: pathophysiology, diagnosis and management. Cureus. Available at: https://doi.org/10.7759/cureus.7385. [Accessed 12 December 2023].
Warkentin TE, Sheppard JI, Linkins L, Callum J, Nazy I. Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL® HIT-Ab (PF4-H)] for the diagnosis of immune heparin-induced thrombocytopenia. Thromb Res 2017; 153:108–117.
Rubino JG, Callum J, Warkentin TE, Smith JW, Kelton JG, Nazy I. A comparative study of platelet factor 4-enhanced platelet activation assays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2021; 19:1096–1102.
Lo G, Juhl D, Warkentin TE, Sigouin C, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4:759–765.
Franco L, Becattini C, Beyer-Westendorf J, Vanni S, Nitti C, Re R, et al. Definition of major bleeding: prognostic classification. J Thromb Haemost 2020; 18:2852–2860.
UpToDate, n.d. UpToDate. Available at: https://www.uptodate.com/contents/argatroban-drug-information?search=argatroban&source=panel_search_result&selectedTitle=1∼44&usage_type=panel&kp_tab=drug_general&display_rank=1. [Accessed 12 December 2023].
Bachler M, Asmis LM, Koscielny J, Lang T, Nowak H, Paulus P, et al. Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review. Blood Coagul Fibrinolysis 2022; 33:239–256.
Lo G, Sigouin C, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007; 82:1037–1043.
Wills NK, Nair N, Patel K, Sikder O, Adriaanse M, Eikelboom JW, Wasserman S. Efficacy and safety of intensified versus standard prophylactic anticoagulation therapy in patients with coronavirus disease 2019: a systematic review and meta-analysis. Open Forum Infect Dis 2022; 9:ofac285.
Kham NI, Shahid R, Naik SS, Ramphall S, Rijal S, Prakash V, et al. The comparison of therapeutic with prophylactic anticoagulation on mortality, risk of bleeding, and thromboembolism in hospitalized patients with COVID-19: a systematic review. Cureus 2022; e29932.
Gabara C, Solarat B, Castro P, Fernández S, Badia JR, Toapanta D, et al. Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients. Med Intensiva 2023; 47:1–8.
Fisser C, Winkler M, Malfertheiner MV, Philipp A, Foltan M, Lunz D, et al. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study. Crit Care 2021; 25:160.
Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. Argatroban anticoagulant therapy in patients with Heparin-Induced thrombocytopenia. Circulation 2001; 103:1838–1843.
Crowther M, Cook DJ, Albert M, Williamson D, Meade MO, Granton J, et al. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 2010; 25:287–293.
Martin KA, Kia L, Parikh ND, Kulik L, McMahon B. Heparin-induced thrombocytopenia testing is over-utilized in cirrhosis & correlates with poor clinical outcomes. Ann Hepatol 2014; 13:548–554.